Skip to main content
Equibles
KYMR logo

KYMR · Kymera Therapeutics, Inc. · Documents

Track KYMR — free

Use KYMR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYMR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$127.17 -7.67 (-5.69%) At close · Nov 12 Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$10.86B
Shares
85.37M
Volume · Nov 12 685.11K Avg daily vol (3M) 823.63K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $39.21M down 16.7% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $0 10-Q filed Oct 29, 2026 Latest results Financial results 8-K filed Oct 29, 2026 Earnings call Q2 2026 earnings call Held Aug 5, 2026
2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
R&D spending rises as quarterly loss widens

Kymera Therapeutics posted a $132.0 million net loss for the quarter ended September 30, 2026 as research and development expenses rose to $128.5 million from $74.1 million. Cash, cash equivalents and marketable securities were $1,646 million, expected to fund operations into 2029.

Revenue $0 Net loss $132M Diluted EPS -$1.32
Read from the MD&A section
3 source passages
We reported net losses of $132.0 million and $262.4 million for the three and nine months ended September 30, 2026 respectively, and $82.2 million and $224.4 million for the three and nine months ended September 30, 2025, respectively. Research and development expenses were $128.5 million for the three months ended September 30, 2026, compared to $74.1 million for the three months ended September 30, 2025. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $1,646 million. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into 2029, beyond multiple clinical inflection points in our pipeline. Open the document at this passage
Oct 29
Current report 8-K
Financial results

Kymera Therapeutics reported third-quarter 2026 results: a $132.0 million net loss and $1.6 billion in cash, cash equivalents and investments as of September 30, 2026. KT-579 Phase 1 results were positive, while KT-621 BROADEN2 topline data are planned by year-end 2026.

Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $65M ▲ 466.4% Net loss $61.21M Diluted EPS -$0.62
Apr 30
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $34.37M ▲ 55.5% Net loss $69.23M Diluted EPS -$0.71
Apr 29
Proxy statement DEF 14A Meeting Jun 24, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $39.21M ▼ 16.7% Net loss $311.35M Diluted EPS -$3.69
2025
Showing 1–50 of 148 documents
Key facts CIK 1815442 CUSIP 501575104 13F (30d) 193 filings 172 filers Visit website Investor relations